Medical aims at the biomedical industry to highlight service to create value

Release date: 2016-10-11

On September 20th, the “Medical Headquarters Base” was officially renamed as “Medical·Three Medical Innovation Center”. At present, the first phase of medical science has completed 80% of investment, and the second phase of the park has been launched. With this change of name, the Medical·Three Medical Innovation Center will provide a more complete industrial service for the park enterprises and industry peers with a new attitude, aiming to become China's first precision medicine incubator, promote industry exchanges and help enterprises. Take off.
 
As the core area of ​​Zone B of Chengdu Medical City, the Medical·Three Medical Innovation Center has gathered bio-organisms, Kaipu Bio, Yishan Bio, Fuji Bio, Century Tongchang, Huiling Xinkang (SR Anticancer Drug), St. Shuan Medical Devices, Xichen Guanghua, Qi Huang Boen and other well-known enterprises and institutions.
 
In the future, the Medical·Three Medical Innovation Center will carry out a full range of industrial services in the field of precision medicine, attracting more high-quality “three medical” industry well-known enterprises to settle in and build the park into a gathering place for biomedical industry.
 
Improve the park's industrial supporting services to create value
 
Since the beginning of this year, the Medical and Three Medical Innovation Center has organized a variety of training sessions, entrepreneurial salons, and talent recruitment meetings with a number of well-known universities and investment and financing institutions such as Chengdu University of Traditional Chinese Medicine and Jiuding Zhiyuan. Create a good development environment for innovative and entrepreneurial enterprises in the biomedical field and build an effective industrial platform.
 
In the future, Chengdu Medical City and Medical·Three Medical Innovation Center will also host more activities to promote the incubation and upgrading of small and medium-sized enterprises and biomedical innovation and entrepreneurship enterprises in the park.
 
In addition, the Medical·Three Medical Innovation Center will focus on the development direction of the industry, highlight the concept of “service creation value”, continuously improve the industrial service chain, and provide government affairs, financing, certification, and services on the basis of improving the supporting services of the park. All-round strategic services such as information and talents.
 
At present, in addition to various high-quality industrial service mechanisms, the Medical·Three Medical Innovation Center has a number of strong preferential policies that have become favorable conditions for attracting enterprises to settle in. This year, Wenjiang District officially issued the "Chengdu Medical City Industry Support Measures" stipulations, Wenjiang District Finance annually arranges Chengdu Medical City industrial development funds of not less than 100 million yuan to support enterprise development.
 
The industrial policy of 100 million yuan in the Medical and Three Medical Innovation Center is undoubtedly a powerful catalyst for enterprises.
 
In addition, in order to encourage and stimulate independent innovation, the Medical·Three Medical Innovation Center strongly supports academicians and high-level talents who are included in the national, provincial and municipal key talent programs, bringing technology, bringing projects, bringing teams to the park to start businesses, and enjoying the country. On the basis of the provincial and municipal support policies, the park will also grant entrepreneurial start-up funds of up to 5 million yuan, 3 million yuan and 2 million yuan respectively after the examination and approval, and fully support talent entrepreneurship.
 
I set up the stage, you sing. The Medical·Three Medical Innovation Center has built a broad development platform for enterprises with multi-faceted, high-level industrial services, strong policy support, and various forms of summit activities to help enterprises become bigger and stronger.
 
Practice "three doctors +" aiming at the biomedical industry
 
“Biomedicine is the most active and active development field in the world today,” said Yu Hui, deputy secretary of the Wenjiang District Committee. In 2015, the global pharmaceutical market totaled more than 1 trillion US dollars. In the next 5-10 years, the overall market size will reach 2.7 trillion US dollars, gradually becoming the leading industry of the world economy.
 
Under the pattern of “one city, one district and many parks” in Chengdu biomedical industry, Chengdu Medical City and Medical·Three Medical Innovation Center are becoming the main front and international cooperation platform for the opening up of biomedicine.
 
According to the plan, Chengdu Medical City will focus on the industrial layout of “one city, two districts, and two wings”. The park area B will focus on medical research and development, focusing on creating “innovative research and development towns” to guide the research and development of medical diagnosis and treatment technology (precise medical treatment). The development of medical device research and development has finally formed the 7 “industry agglomeration zones”. Among them, R&D 1st, 2nd, 3rd, and 4th districts mainly develop precision medical and contract research and development industrial projects; comprehensive service supporting areas develop third-party professional services, public platforms and other industrial platform projects, and medical institutions gather areas to develop high-quality specialist medical care, Rehabilitation institutions, full-cycle health management industry projects; medical and health complexes to develop new medical health service industry projects.
 
Today, the Medical·Three Medical Innovation Center has settled in more than 20 companies, including well-known leading enterprises in the industries such as Huada Gene, WuXi PharmaTech, Shenggong Bio, Kaipu Bio, Yishan Bio, and Yuandong Bio.
 
In the future, the Medical·Three Medical Innovation Center will continue to target the biomedical industry, and serve the medical and medical industries in an all-round way with the core development concept of “Three Medicines+”, and build China's first precision medicine that integrates incubation, production, management and service. The whole industry chain incubator.

Source: Medicine Network

Veterinary medicine

Veterinary drugs: refers to substances (including medicated feed additives) used to prevent, treat, diagnose animal diseases or purposefully regulate animal physiological functions.
Veterinary drugs mainly include: serum products, vaccines, diagnostic products, micro-ecological products, Chinese herbal medicines, proprietary Chinese medicines, chemicals, antibiotics, Biochemical drugs, radioactive drugs and topical pesticides, disinfectants, etc. veterinary drug
Also known as veterinary drugs or animal drugs, in a narrow sense, it refers to drugs for livestock and poultry, and in a broad sense, it refers to drugs that prevent and treat all animal diseases except humans and promote their growth and reproduction. The research and development of veterinary drugs and human drugs promote each other and develop synchronously.
China's "Handbook of Veterinary Drugs" (1977 edition) contains APIs and a total of 1,300 varieties, the US "Veterinary Drug Index" contains 460 types of veterinary APIs, the "British Veterinary Pharmacopoeia" contains 210 types of APIs, and more than 130 kinds of preparations and 40 kinds of biochemical immune products. In 1979, Japan produced, sold and imported about 1,900 varieties of veterinary drugs.

Veterinary medicine,Niclosamide for Sale,Niclosamide for Humans,Albendazole 400 Mg,Oxfendazole for Dogs

Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikang.com